Study Information

Alliance Study ID: NCCTG-N0877

NCT Study ID (ClinicalTrials.gov): NCT00869401

Alliance Committee: Neuro-Oncology

Disease or Cancer Type: Brain / Central Nervous System Cancer

Alliance Study Chair: Nadia N. Laack, MD

Status: COMPLETED


Study Description

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. This randomized phase I/II trial is studying the best dose of dasatinib and to see how well it works compared with a placebo when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials